Skip to main content

drug discovery Archives

Slides can help faculty with Ancora proposal submissions

May. 10, 2018—The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals.

Read more


Looking beyond the ‘magic bullet’ approach to drug discovery

May. 1, 2018—Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

Read more


Nashville Biosciences created to leverage wealth of data

Apr. 5, 2018—Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.

Read more


Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer

Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

Read more


What’s On My Mind: America’s partnership with its research universities fuels our common future

Feb. 15, 2018—The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos.

Read more


Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more


Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs

Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.

Read more


Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Read more


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more


Vanderbilt, Ono Pharmaceutical extend drug discovery agreement

May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.

Read more


New method for tapping vast plant pharmacopeia to make more effective drugs

Apr. 14, 2017—Geneticists have developed an effective new method for identifying the genes that produce the chemicals plants use to protect themselves from predators, which are an important natural drug source.

Read more


Fighting fungal infections

Apr. 3, 2017—A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments.

Read more


Upcoming Events

MORE EVENTS »